Three CDMOs Form Integrated CMC Partnership to Accelerate Drug Development from Discovery to Clinic
核心洞察
Sai Life Sciences (搜索), Agility Life Sciences (搜索), and Centrix Pharma Solutions (搜索) have launched an Integrated CMC Partnership to provide end-to-end Chemistry, Manufacturing and Controls services for biopharma companies.
The collaboration combines Sai's API development expertise, Agility's formulation development capabilities, and Centrix's drug product development and clinical manufacturing services.
The partnership aims to streamline drug development from preclinical studies to first-in-human clinical trials by reducing duplication, risks, costs, and timelines through integrated planning.
Sai Life Sciences (搜索), Agility Life Sciences (搜索), and Centrix Pharma Solutions (搜索) announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with comprehensive Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the specialized expertise of each organization to create an end-to-end solution spanning from preclinical studies to first-in-human clinical trials and beyond.
Strategic Alliance Combines Complementary Expertise
The partnership leverages the distinct capabilities of each organization: Sai Life Sciences (搜索) contributes extensive API development expertise, Agility Life Sciences (搜索) brings formulation development capabilities, and Centrix Pharma Solutions (搜索) provides drug product development and clinical manufacturing services. This integrated approach enables customers to access unified drug substance and drug product development services through a single collaborative framework.
According to Krishna Kanumuri (搜索), MD & CEO of Sai Life Sciences (搜索), "We are delighted to partner with Agility Life Sciences (搜索) and Centrix Pharma in this truly integrated CMC offering. By bringing together our complementary strengths, we can deliver far greater value to innovators—helping them translate ideas into medicines with speed, quality, and efficiency."
Comprehensive Service Portfolio Addresses Industry Challenges
The Integrated CMC Partnership offers broad scientific expertise across multiple disciplines, supported by extensive laboratory and manufacturing facilities. The collaboration provides end-to-end service coverage from synthetic route scouting to drug substance manufacturing, and from pre-formulation through to clinical trial material manufacturing.
Key operational advantages include cross-functional optimization through integrated planning across API and drug product development, which reduces duplication, risks, costs, and timelines. The partnership also emphasizes agility and flexibility to respond proactively to emerging technical risks across functions, with seamless coordination between technical teams including proactive sample transfer and early API evaluation in the drug product process.
Dr. Claire Thompson, CEO and Founder of Agility Life Sciences (搜索), stated, "We are delighted to be entering this partnership with Sai and Centrix. Our combined expertise and energy will enable our clients' molecules to be accelerated through key milestones, while reducing risk and cost."
Streamlined Project Management and Execution
The partnership establishes a single point of contact from Day One, ensuring alignment and accountability throughout project execution. This approach creates what the companies describe as a faster, more efficient, and more collaborative pathway for innovators to advance their drug candidates with confidence.
Chris Davison (搜索), CEO of Centrix Pharma Solutions (搜索), emphasized the collaborative nature of the alliance: "What excites me most about this partnership is the spirit of collaboration it represents. By bringing together talented teams across Sai, Agility, and Centrix, we are creating a seamless environment where expertise flows freely, challenges are solved collectively, and clients benefit from true alignment."
Industry Context and Company Profiles
Sai Life Sciences (搜索) operates as a leading integrated Contract Research, Development & Manufacturing Organization (CRDMO) working with over 300 innovator pharma and biotech companies globally. The company employs over 3,400 people across state-of-the-art facilities in India, the UK, and the USA, focusing on accelerating the discovery, development, and manufacture of complex small molecules.
Agility Life Sciences (搜索) specializes in formulation development as an award-winning CDMO, helping pharmaceutical and biotech companies overcome bioavailability, stability, and delivery challenges. The company's "Fast Futureproof Formulations" approach creates tailored formulations designed to enable molecules to progress rapidly into and through clinical development.
Centrix Pharma Solutions (搜索) operates as a specialist CDMO focused on drug product development and clinical trial manufacturing, building on decades of expertise to provide science-driven, patient-centric solutions that accelerate the journey from molecule to medicine.